CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-16 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −400 | $150.10 | $60K | 7,507 |
| 2024-07-16 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 | +1,557 | $103.52 | $161K | 9,064 |
| 2024-07-16 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −1,557 | $150.00 | $234K | 7,507 |
| 2024-07-16 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −900 | $150.04 | $135K | 6,607 |
| 2024-07-16 | Delaet Ingrid Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −400 | 26,649 | ||
| 2024-07-16 | Delaet Ingrid Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −1,557 | 25,092 | ||
| 2024-07-16 | LYONS GARY A Director | Option exercise 10b5-1 | +930 | $42.76 | $40K | 119,977 |
| 2024-07-16 | LYONS GARY A Director | Sale 10b5-1 | −930 | $150.03 | $140K | 119,047 |
| 2024-07-16 | LYONS GARY A Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −930 | 11,570 | ||
| 2024-07-16 | ABERNETHY MATT Chief Financial Officer | Option exercise 10b5-1 | +900 | $73.60 | $66K | 32,428 |
| 2024-07-16 | ABERNETHY MATT Chief Financial Officer | Sale 10b5-1 | −900 | $150.04 | $135K | 31,528 |
| 2024-07-16 | ABERNETHY MATT Chief Financial Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −900 | 14,100 | ||
| 2024-07-16 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 | +7,004 | $79.02 | $553K | 46,744 |
| 2024-07-16 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 | −7,004 | $150.00 | $1.1M | 39,740 |
| 2024-07-16 | Lippoldt Darin Chief Legal Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −7,004 | 46,368 | ||
| 2024-07-01 | Cooke Julie Chief Human Resources Officer | Option exercise 10b5-1 | +10,000 | $61.82 | $618K | 28,202 |
| 2024-07-01 | Cooke Julie Chief Human Resources Officer | Sale 10b5-1 | −10,000 | $140.19 | $1.4M | 18,202 |
| 2024-07-01 | Cooke Julie Chief Human Resources Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −10,000 | 13,532 | ||
| 2024-07-01 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 | +272 | $79.02 | $21K | 7,779 |
| 2024-07-01 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −272 | $138.11 | $38K | 7,507 |
Page 30 of 49 · 963 trades